Trials / Active Not Recruiting
Active Not RecruitingNCT04756648
Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma
An Open, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0180 Injection in Patients With Advanced Hepatocellular Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I Clinical Study ofCT0180 cells in Patients with Advanced Hepatocellular Carcinoma
Detailed description
Primary objectives: Evaluate the safety and tolerance of CT0180 cells in patients with advanced hepatocellular carcinoma within 28 days after the first infusion Secondary objectives: * Evaluate the metabolic kinetics of CT0180 cells ; · Evaluate overall safety and tolerability ; · Evaluate the initial efficacy of CT0180 cell infusion in the treatment of advanced hepatocellular carcinoma with positive Glypican-3（GPC3 ）expression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT0180 Cells | Five dose levels were tentatively determined. |
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2023-03-31
- Completion
- 2026-06-01
- First posted
- 2021-02-16
- Last updated
- 2025-09-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04756648. Inclusion in this directory is not an endorsement.